Growth Factors

Growth factors are naturally occurring, secreted proteins that bind to specific cell surface receptors to regulate key cellular processes such as proliferation, differentiation, survival, and migration. They are produced by many different cell types and act on target cells to activate intracellular signaling pathways that regulate gene expression.

Growth factors can mediate autocrine, paracrine, juxtacrine, and endocrine signaling. Through autocrine or paracrine mechanisms, they influence the local tissue environment by acting on the cells that produce them or on nearby cells, respectively.  Some growth factors can also mediate juxtacrine signaling through direct cell-cell contact or endocrine signaling by entering the circulation and acting on distant target tissues. 

Growth factors regulate cell proliferation by activating signaling pathways that promote cell cycle progression. They also guide differentiation by triggering gene expression programs that define specialized cell types. This dual role ensures proper tissue growth and regeneration.

Growth factor signaling plays a critical role in cancer initiation, progression, and metastasis. In many tumors, growth factors and their receptors become dysregulated, enabling cancer cells to sustain proliferation, evade cell death, stimulate angiogenesis, and remodel the tumor microenvironment. As a result, growth factor pathways remain important areas of investigation for understanding disease mechanisms and identifying new therapeutic strategies.

Researchers are actively studying signaling networks involving the epidermal growth factor (EGF), vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF), hepatocyte growth factor (HGF), platelet-derived growth factor (PDGF), and transforming growth factor-beta (TGF-β) families. These pathways regulate key processes such as tumor growth, blood vessel formation, cell migration, and immune modulation, making them attractive targets for therapeutic intervention.

While growth factor pathways such as HGF/c-MET, FGF/FGF R, PDGF/PDGF R, and TGF-β/TGF-β R have long been recognized for their roles in tumor growth and progression, current research is focused on understanding how dysregulation of these same pathways contributes to treatment resistance, metastasis, and disease recurrence. Researchers are investigating how growth factor signaling shapes communication between cancer cells and the surrounding tumor microenvironment, influencing processes including epithelial to mesenchymal transition (EMT), immune modulation, stromal remodeling, and cancer stem cell maintenance. These studies may reveal new opportunities to improve therapeutic responses and achieve more durable clinical outcomes. 

Growth factors are central regulators of angiogenesis, the process by which new blood vessels form from existing vasculature. Under normal physiological conditions, angiogenesis supports embryonic development, tissue repair, wound healing, and regeneration. In disease, however, dysregulated growth factor signaling can drive pathological angiogenesis, resulting in the formation of abnormal blood vessels that contribute to disease progression. Key angiogenic growth factors include members of the VEGF, FGF, PDGF, HGF, and TGF-β families. These signaling pathways collectively coordinate endothelial cell proliferation, migration, survival, vascular permeability, and vessel maturation.

Among these pathways, VEGF signaling is the master regulator of angiogenesis. VEGF-A binding to VEGF R2 stimulates endothelial cell activation and the formation of new blood vessels, while FGF, PDGF, and HGF signaling contributes to endothelial cell growth, vessel stabilization, and recruitment of supporting mural cells. Tumors and chronically inflamed tissues often exploit these pathways to establish a blood supply that provides oxygen and nutrients while facilitating disease progression.

Pathological angiogenesis is most heavily studied in cancer and retinal diseases, with the VEGF/VEGF R pathway serving as the primary therapeutic target. However, increasing evidence suggests that the FGF/FGF R, PDGF/PDGF R, HGF/c-MET, TGF-β, and Angiopoietin/Tie-2 pathways can compensate for VEGF inhibition, making them important emerging targets for next-generation anti-angiogenic therapies.

Growth factors are essential regulators of tissue repair and regeneration, coordinating the cellular and molecular processes required to restore damaged tissues after injury. Following tissue damage, growth factors such as PDGF, EGF, FGFs, TGF-β, and VEGF are released by platelets, immune cells, and local tissue cells. These signaling molecules stimulate the proliferation, migration, and differentiation of reparative cells, including fibroblasts, epithelial cells, endothelial cells, and tissue-specific progenitor cells. They also promote the recruitment of immune cells that clear debris and coordinate the transition from inflammation to healing, creating an environment that supports effective tissue regeneration and restoration of function.

A critical function of growth factors in wound healing and tissue regeneration is the promotion of angiogenesis. As previously mentioned, growth factors stimulate endothelial cell proliferation and migration, increasing blood supply to injured tissues and delivering oxygen, nutrients, and signaling molecules necessary for repair. At the same time, growth factors regulate extracellular matrix (ECM) remodeling, collagen deposition, and the formation of vascularized granulation tissue, creating the structural framework that supports tissue repair and regeneration. The coordinated activity of these pathways accelerates wound closure, enhances tissue integrity, and improves functional recovery following injury. 

Beyond acute wound healing, growth factors play a central role in regenerative medicine, where they are being investigated as therapeutic agents to promote tissue regeneration in skin, bone, muscle, nerve, and cardiovascular tissues. By activating signaling pathways that control stem cell activity, cell survival, tissue remodeling, and vascular regeneration, growth factors help drive the repair of damaged organs and support long-term tissue restoration. Ongoing research continues to explore how growth factor signaling can be harnessed to improve regenerative therapies and enhance healing outcomes in chronic wounds, degenerative diseases, and complex tissue injuries.

Growth factors are key regulators of fibrosis, controlling the cellular and molecular processes that drive tissue scarring and extracellular matrix (ECM) accumulation. Following tissue injury, growth factors help coordinate normal wound healing by promoting fibroblast proliferation, migration, and matrix production. However, persistent or dysregulated growth factor signaling can lead to chronic fibroblast activation, differentiation of fibroblasts into ECM-producing myofibroblasts, and excessive deposition of collagen and other matrix proteins. Among these factors, TGF-β is widely recognized as a master regulator of fibrosis, while PDGFs, connective tissue growth factor (CTGF/CCN2), VEGFs, and specific FGFs also contribute to fibroblast activation, tissue remodeling, angiogenesis, and the progression of fibrotic disease. Because aberrant growth factor signaling is a hallmark of fibrotic disorders affecting the lungs, liver, kidney, heart, and other organs, these pathways are actively being investigated as therapeutic targets for the prevention and treatment of fibrosis. 

Growth factors are critical regulators of neuronal survival, differentiation, synaptic plasticity, and tissue repair in the nervous system. In neurodegenerative diseases such as Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis (ALS), and Huntington’s disease, dysregulated growth factor signaling can impair neuronal survival, synaptic function, and tissue repair processes. Neurotrophic factors, including brain-derived neurotrophic factor (BDNF), nerve growth factor (NGF), glial cell line-derived neurotrophic factor (GDNF), and insulin-like growth factor-I (IGF-I), support neuronal health by activating signaling pathways that promote cell survival, axonal growth, and neuroplasticity. Reduced expression or impaired signaling of these factors has been associated with progressive neuronal loss and cognitive or motor decline in multiple neurodegenerative disorders. 

Beyond their direct effects on neurons, growth factors also influence neuroinflammation, vascular function, and tissue repair responses within the central nervous system. VEGF, FGFs, and other growth factor families regulate angiogenesis, neurogenesis, neural stem cell activity, and signaling interactions among neurons, glial cells, and the extracellular matrix. As disrupted growth factor signaling has been implicated in the progression of numerous neurodegenerative diseases, growth factor pathways are actively being investigated as therapeutic targets to promote neuroprotection, support neural repair, and slow disease progression.